
Servier UK appoints new chief executive
pharmafile | December 18, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Arnaud Lallouette, Mike Sumpter, Servier
Dr Arnaud Lallouette has been appointed chief executive of Servier Laboratories, the UK subsidiary of the French-based pharma firm, after current chief exec Mike Sumpter moved to a new role within the company.
Dr Lallouette has been with Servier Group for twenty years, and will make the transition from general manager of Servier Scandinavia on January 1. He will have responsibility for Servier UK’s return to the diabetes arena, and Servier UK’s first launch of an oncology product.
Meanwhile Sumpter will be taking up a new role at the company’s headquarters in Paris, as head of alliance management, following seven years as chief exec of Servier UK, before which he spent seven years as head of Servier Canada. He will be leading a team tasked with effectively managing Servier’s external collaborations. Following the relocation he will also step down from his position from the board of management at the ABPI.
Sumpter says: “As business development and licensing assumes an increasing role within Servier’s activities, effective alliance management will be key to optimal outcomes for these collaborations.”
Related Content

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins
French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced …

Servier and MiNA partner to develop neurological disorder treatments
Independent pharmaceutical group Servier and RNA activation-focused MiNA Therapeutics have entered a research partnership to …






